Business Description
Exelixis is a US-based cancer treatment company that develops and sells medicines for hard-to-treat cancers, with its core products built around cabozantinib, a compound that blocks multiple proteins known to drive tumor growth. Its approved treatments target advanced kidney cancer, thyroid cancer, and certain forms of melanoma, while a broader pipeline of newer drug candidates is currently in development. The company works alongside a number of major pharmaceutical partners and has been operating from its headquarters in Alameda, California since 1994.
